Biogen's Alzheimer's drug succeeds in mid-stage trial

(Reuters) - Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.